dc.creator | Bachurin S.O. | |
dc.creator | Gavrilova S.I. | |
dc.creator | Samsonova A. | |
dc.creator | Barreto G.E. | |
dc.creator | Aliev G. | |
dc.date.accessioned | 2020-09-02T22:12:35Z | |
dc.date.accessioned | 2022-11-08T20:22:41Z | |
dc.date.available | 2020-09-02T22:12:35Z | |
dc.date.available | 2022-11-08T20:22:41Z | |
dc.date.created | 2020-09-02T22:12:35Z | |
dc.date.issued | 2018 | |
dc.identifier | 129, , 216-226 | |
dc.identifier | 10436618 | |
dc.identifier | https://hdl.handle.net/20.500.12728/3664 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5144523 | |
dc.language | en | |
dc.publisher | Academic Press | |
dc.subject | Alzheimer's disease | |
dc.subject | Clinical trial and AD treatment | |
dc.subject | Disease-modifying drugs | |
dc.subject | Multitargeting compounds | |
dc.subject | Neurodegenerative disease | |
dc.subject | Repositioning of old drugs | |
dc.subject | ABC transporter subfamily B | |
dc.subject | alicapistat | |
dc.subject | an 2 | |
dc.subject | ban 2401 | |
dc.subject | bca 909 | |
dc.subject | bosutinib | |
dc.subject | brexanolone | |
dc.subject | df 302 | |
dc.subject | donepezil | |
dc.subject | elenbecestat | |
dc.subject | gre 213 | |
dc.subject | itanapraced | |
dc.subject | ladostigil | |
dc.subject | levetiracetam | |
dc.subject | ly 2599666 | |
dc.subject | ly 3002813 | |
dc.subject | microRNA | |
dc.subject | montelukast | |
dc.subject | neuroprotective agent | |
dc.subject | nnz 2591 | |
dc.subject | phenserine | |
dc.subject | pioglitazone | |
dc.subject | sar 228810 | |
dc.subject | suvn 502 | |
dc.subject | tak 71 | |
dc.subject | tesamorelin | |
dc.subject | tropisetron | |
dc.subject | ue 2343 | |
dc.subject | unclassified drug | |
dc.subject | unindexed drug | |
dc.subject | verubecestat | |
dc.subject | biological marker | |
dc.subject | Alzheimer disease | |
dc.subject | cerebrospinal fluid analysis | |
dc.subject | cholinergic nerve cell | |
dc.subject | disease course | |
dc.subject | drug effect | |
dc.subject | drug screening | |
dc.subject | human | |
dc.subject | metabolomics | |
dc.subject | mild cognitive impairment | |
dc.subject | nerve cell lesion | |
dc.subject | nerve degeneration | |
dc.subject | neuroimaging | |
dc.subject | nonhuman | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | risk factor | |
dc.subject | animal | |
dc.subject | cognitive defect | |
dc.subject | metabolism | |
dc.subject | Alzheimer Disease | |
dc.subject | Animals | |
dc.subject | Biomarkers | |
dc.subject | Cognitive Dysfunction | |
dc.subject | Humans | |
dc.title | Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention | |
dc.type | Review | |